AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

After rapid expansion, signs of a slowdown raise questions about future opportunities in the sector When it emerged that ...

AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early stage ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...

AstraZeneca PLC has agreed to pay $51 million to settle claims it entered into an unlawful deal to limit competition for ...

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

The Cambridge Biomedical Campus – already the largest centre of medical research and health science in Europe – could double ...

The winners of the RIBA East Awards 2025 were unveiled at a ceremony on 15 May, at which Young’s Court Development at ...